Online citations, reference lists, and bibliographies.

Treatment Of Vulvovaginal Candidiasis: A Review Of The Literature.

A. Dovnik, Andrej Golle, D. Novak, D. Arko, I. Takac
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Vulvovaginal candidiasis (VVC) affects around three-quarters of all women during their reproductive age, although the exact incidence of VVC is difficult to determine because many patients are self-treated. The infections are divided into complicated and uncomplicated. Uncomplicated VVC is most effectively treated with local azoles. Oral treatment with a single dose of fluconazole is also effective for treating uncomplicated VVC. Treatment of complicated VVC is prolonged and most commonly consists of multiple doses of oral fluconazole or at least 1 week of local azoles. The role of probiotics in treating VVC is still disputed. This article presents a review of the literature on the various treatment options for VVC. Treatment for the most common pathogens that cause complicated VVC is also discussed.
This paper references
10.2105/AJPH.80.3.329
The epidemiology of vulvovaginal candidiasis: risk factors.
B. Foxman (1990)
10.1055/S-0034-1368243
Three-Day Combination Treatment for Vulvovaginal Candidosis with 200 mg Clotrimazol Vaginal Suppositories and Clotrimazol Cream for the Vulva is Significantly Better than Treatment with Vaginal Suppositories Alone - an Earlier, Multi-Centre, Placebo-Controlled Double Blind Study.
W. Mendling (2014)
10.1097/00006254-200201000-00014
Treatment of complicated Candida vaginitis: Comparison of single and sequential doses of fluconazole
J. Sobel (2002)
10.1080/00016340600578357
Lactobacilli in the female genital tract in relation to other genital microbes and vaginal pH.
Per Daniel Johannes Rönnqvist (2006)
10.1067/S0002-9378(03)00726-9
Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine.
J. Sobel (2003)
10.1136/bmj.1.5017.517-b
Vaginitis
Stanley A. Bond (1957)
10.1086/596757
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Peter G. Pappas (2009)
10.1037/e528752006-001
Sexually transmitted diseases treatment guidelines, 2006.
K. Workowski (2006)
Clinical practice guidelines for the management of candidiasis :
PG Pappas (2014)
10.1016/j.ejogrb.2012.12.031
Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study.
Goran Vujić (2013)
10.1056/NEJMOA033114
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.
J. Sobel (2004)
10.1016/S0002-9378(98)80001-X
Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations.
J. Sobel (1998)
10.1016/j.ejogrb.2014.09.018
Lactobacillus plantarum P17630 for preventing Candida vaginitis recurrence: a retrospective comparative study.
F. de Seta (2014)
10.1093/JAC/DKL246
Probiotics for prevention of recurrent vulvovaginal candidiasis: a review.
M. Falagas (2006)
10.1136/BMJ.328.7451.1306
Vaginal discharge—causes, diagnosis, and treatment
H. Mitchell (2004)
10.1111/j.1472-765X.2008.02477.x
Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.
R. Martinez (2009)
10.1080/00365540601148491
Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods
Meryem Çetin (2007)
10.1016/j.jiph.2011.05.006
Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis.
L. Sekhavat (2011)
10.1128/jcm.34.10.2497-2499.1996
Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis.
J. Sobel (1996)
10.1016/S0016-5085(84)80021-9
Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases.
J. Lewis (1984)
10.1016/S0301-2115(98)00123-7
The frequency of bacterial and yeast infection in women with different grades of cervical intraepithelial neoplasia (CIN).
I. Takac (1998)
update by the Infectious Diseases Society of America
PD Ronnqvist (2009)
10.1001/JAMA.291.11.1368
Evaluation of vaginal complaints.
M. Anderson (2004)
Candidiasis (vulvovaginal).
D. Spence (2007)
10.1016/J.AJOG.2005.03.034
Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories.
A. J. Phillips (2005)
10.1371/journal.ppat.1003965
Candida Vaginitis: When Opportunism Knocks, the Host Responds
B. M. Peters (2014)
10.1111/j.1439-0507.2011.02030.x
Recurrent vulvovaginal candidosis: focus on the vulva.
F. Beikert (2011)
10.1097/00006254-200301000-00014
Prevalence of Vulvovaginal Candidiasis and Susceptibility to Fluconazole in Women
T. Bauters (2003)
10.1097/00001648-199603000-00013
Risk Factors for Vulvovaginal Candidiasis: A Case- Control Study among University Students
A. Geiger (1996)
10.1007/s11046-014-9827-4
Vaginal Nystatin Versus Oral Fluconazole for the Treatment for Recurrent Vulvovaginal Candidiasis
Shangrong Fan (2014)
10.1111/j.1471-0528.2009.02262.x
Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial
A. Witt (2009)
Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis.
J. Sobel (1985)
10.1007/978-3-642-83312-0
Vulvovaginal Candidosis
Dr. Werner Mendling (1988)
Candida Infections of the Genitourinary Tract
V. Sangamithra (2013)
10.1016/j.annemergmed.2011.04.006
Sexually transmitted diseases treatment guidelines, 2010.
K. Workowski (2010)



This paper is referenced by
10.1016/J.APJTB.2015.08.002
ERG11 mutations associated with azole resistance in Candida albicans isolates from vulvovaginal candidosis patients
B. Wang (2015)
10.21019/9781582122250.CH8
Chapter 8: Vaginal and Vulvovaginal Disorders
Nicole M. Lodise (2015)
10.5455/jicm.2.20160425
Prevalence of vulvovaginal candidiasis and treatment with isoconazol nitrate
Türkan Toka Özer (2018)
10.1186/s12866-018-1370-x
Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis
Hong Liao (2018)
10.1007/s12281-019-00357-3
Update of Vulvovaginal Candidiasis in Pregnant and Non-pregnant Patients
Tito Ramírez-Lozada (2019)
10.3892/etm.2017.5518
Research of Mrr1, Cap1 and MDR1 in Candida albicans resistant to azole medications
Wenli Feng (2018)
10.1007/s10096-016-2715-8
Is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504)
S Palacios (2016)
10.1007/s10103-019-02782-9
Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation
Mariana Robatto (2019)
10.2147/IDR.S175588
Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis
Fen Qin (2018)
10.1111/myc.12883
Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment
R. Russo (2019)
10.1016/j.annepidem.2017.08.010
Recurrent vulvovaginal candidiasis.
Freida A Blostein (2017)
10.7726/JCI.2016.1001
Effects of Probiotics against Candida Infections and Their Potential Use in Vulvovaginal Candidosis
Filippo Fassio (2016)
10.3389/fmicb.2019.01033
Local Probiotic Lactobacillus crispatus and Lactobacillus delbrueckii Exhibit Strong Antifungal Effects Against Vulvovaginal Candidiasis in a Rat Model
Ting Li (2019)
10.3109/10837450.2016.1163385
Mucoadhesive in situ gel formulation for vaginal delivery of clotrimazole: formulation, preparation, and in vitro/in vivo evaluation
Seda Rençber (2017)
10.14393/BJ-V33N2-33681
Study of the antifungal potential of (r)-(+)-citronellal and its association with therapeutic agents used in the treatment of vulvovaginal candidiasis = Estudo do potencial antifúngico do (r)-(+)-citronelal e sua associação com agentes terapêuticos utilizados no tratamento da candidíase vulvovaginal
Cássio Ilan Soares Medeiros (2017)
Desenvolvimento tecnológico de supositórios vaginais contendo nanopartículas poliméricas de tioconazol
Luciana Filippin Cossetin (2015)
10.1155/2018/9703754
Risk Factors of Vulvovaginal Candidiasis among Women of Reproductive Age in Xi'an: A Cross-Sectional Study
Xianling Zeng (2018)
10.18502/cmm.5.4.2062
Species distribution and susceptibility profiles of Candida species isolated from vulvovaginal candidiasis, emergence of C. lusitaniae
Seyed Yaser Hashemi (2019)
10.1007/978-3-030-11815-0_44
Diabetes and Infection
Atulya Atreja (2019)
10.1101/605857
In Vitro Potent Activity of ε-poly-L-lysine against Candida albicans and the Underlying Mechanisms
L. Wei (2019)
10.1002/14651858.CD013012
Nifuratel‐Nystatin combination for the treatment of mixed infections of bacterial vaginosis, vulvovaginal candidiasis, and trichomonal vaginitis
J. Obiero (2018)
10.3389/fmicb.2019.02976
Nanocarriers Provide Sustained Antifungal Activity for Amphotericin B and Miltefosine in the Topical Treatment of Murine Vaginal Candidiasis
Fernanda Walt Mendes da Silva de Bastiani (2019)
10.1016/j.mycmed.2019.100895
Vulvovaginal candidiasis among symptomatic women of childbearing age attended at a Medical Analysis Laboratory in Franceville, Gabon.
M. Bignoumba (2019)
10.17392/1098-20
The effect of Aloe vera ethanol extract on the growth inhibition of Candida albicans.
Via Karina Nabila (2020)
10.13005/BPJ/864
Therapeutic Effects of Bunium Perscicum Boiss (Black Zira) on Candida albicans Vaginitis
Sareh Mehni (2015)
10.1177/1745505717731011
Role of female intimate hygiene in vulvovaginal health: Global hygiene practices and product usage
Ying Chen (2017)
10.1007/978-3-319-45134-3_75-1
Fungal Skin Infections (Mycology)
Asja Prohić (2019)
Semantic Scholar Logo Some data provided by SemanticScholar